TY - JOUR
T1 - Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients
AU - Montanari, N. R.
AU - Conceição-Neto, N.
AU - Van Den Wyngaert, I.
AU - Van Oord, G. W.
AU - Groothuismink, Z. M. A.
AU - Van Tilburg, S.
AU - De Man, R. A.
AU - Aerssens, J.
AU - Boonstra, A.
N1 - Publisher Copyright:
© 2020 The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
PY - 2022/4/15
Y1 - 2022/4/15
N2 - Long-term viremia control in chronic HBV patients occurs either spontaneously in inactive carrier (IC) patients or therapy-induced by nucleos(t)ide analogues (NUC). To better understand the characteristics of viremia control, we evaluated gene expression in purified leukocyte subsets from IC versus NUC-treated patients, and evaluated the putative modulatory effects of hepatitis B surface antigen (HBsAg). We observed that gene expression in NUC-treated patients differed markedly from IC patients, especially in dendritic cells, monocytes, and CD8+ T cells, while serum HBsAg levels had little effect. Nevertheless, based on our findings it cannot be excluded that HBsAg may act locally in the infected liver or preferentially affects HBV-specific cells.
AB - Long-term viremia control in chronic HBV patients occurs either spontaneously in inactive carrier (IC) patients or therapy-induced by nucleos(t)ide analogues (NUC). To better understand the characteristics of viremia control, we evaluated gene expression in purified leukocyte subsets from IC versus NUC-treated patients, and evaluated the putative modulatory effects of hepatitis B surface antigen (HBsAg). We observed that gene expression in NUC-treated patients differed markedly from IC patients, especially in dendritic cells, monocytes, and CD8+ T cells, while serum HBsAg levels had little effect. Nevertheless, based on our findings it cannot be excluded that HBsAg may act locally in the infected liver or preferentially affects HBV-specific cells.
UR - http://www.scopus.com/inward/record.url?scp=85127536359&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiaa614
DO - 10.1093/infdis/jiaa614
M3 - Article
C2 - 33009569
SN - 0022-1899
VL - 225
SP - 1471
EP - 1476
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 8
ER -
